Business, energy, technology, markets and global industry news from Business News Today

immuno-oncology

PharmaDeviceNews immuno-oncology
Representative image: AstraZeneca’s Imfinzi approval with BCG brings immunotherapy into earlier bladder cancer care, reshaping treatment options for high-risk non-muscle-invasive bladder cancer.
Pharma & Biotech

Imfinzi approval gives AstraZeneca a first immunotherapy combination in early bladder cancer

Imfinzi moves into early bladder cancer, but can AstraZeneca turn a DFS win into real-world bladder-preserving impact?

Read More
Pharma & Biotech

Can Akeso’s ivonescimab ASCO plenary data reset expectations in lung cancer?

Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.

Read More
Pharma & Biotech

Can Leads Biolabs turn Opamtistomig into a frontline EP-NEC treatment contender?

EP-NEC has no approved drug worldwide. Leads Biolabs now has to prove Opamtistomig can turn rare-tumor urgency into regulatory momentum.

Read More
Representative image: A clinical researcher reviews liver cancer scan data in an oncology research setting, illustrating the growing focus on Agenus’ botensilimab and balstilimab combination in post-immunotherapy hepatocellular carcinoma treatment.
Pharma & Biotech

Can Agenus turn botensilimab and balstilimab into a serious post-ICI liver cancer contender?

Post-ICI liver cancer has few strong options. Agenus’ BOT plus BAL data raise the next question: can durability survive larger trials?

Read More
Pharma & Biotech

What Can-Fite BioPharma Ltd.’s Phase 2b pancreatic cancer strategy reveals about immunotherapy combination economics

Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.

Read More
Representative image of anchored monoclonal antibody immunotherapy targeting the cancer tumor microenvironment, illustrating how Ankyra Therapeutics’ preclinical platform aims to improve local drug retention while reducing systemic toxicity.
Pharma & Biotech

Ankyra Therapeutics targets a bigger immunotherapy problem with anchored monoclonal antibodies

Cancer antibodies can be powerful but toxic. Ankyra’s anchored platform asks whether local retention can widen immunotherapy’s safety window.

Read More
Representative image: Oncology researchers reviewing head and neck cancer imaging data, reflecting the clinical focus of Inhibrx Biosciences’ INBRX-106 HexAgon study update in first-line HNSCC and the broader immuno-oncology race to improve pembrolizumab-based treatment strategies.
Pharma & Biotech

Inhibrx’s HexAgon study may test whether smarter OX40 design can beat old failures

OX40 biology has promised more than it proved. Inhibrx now needs INBRX-106 to show pembrolizumab can work harder in HNSCC.

Read More
Representative image: Harbour BioMed’s FDA-cleared HBM7004 IND highlights the growing race to develop B7-H4xCD3 bispecific antibodies for advanced solid tumors, as biotech firms test whether next-generation immunotherapies can improve cancer treatment options beyond conventional approaches.
Pharma & Biotech

HBM7004 FDA clearance gives Harbour BioMed a fresh solid tumor immunotherapy test

Solid tumor T-cell engagers still face safety limits. Harbour BioMed’s HBM7004 now tests whether B7-H4 can widen that window.

Read More
Pharma & Biotech

How AIM ImmunoTech Inc. is positioning Ampligen to overcome checkpoint inhibitor resistance in ovarian cancer

Can AIM ImmunoTech Inc.’s Ampligen improve checkpoint inhibitor responses in ovarian cancer? Explore the Phase 2 findings and implications.

Read More
Pharma & Biotech

Can Annamycin bridge cytotoxic therapy and immunotherapy in pancreatic cancer?

Find out how Annamycin could bridge chemotherapy and immunotherapy in pancreatic cancer and what AACR 2026 data signals for future trials.

Read More